2018 Generic Drugs Market Intelligence: Leading Companies Capabilities, Goals and Strategies
This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation to the leading competitors.
The series includes current assessments of more than 1,000 companies worldwide. Depending on the companys business nature and structure, the assessments include all or some of the following analyses: Organization and Management, Acquisitions and Divestitures, Facilities and Employees, Research and Development, Technological Know-How, Key Products, Marketing Capabilities, Financial Results, Strengths and Weaknesses, and Strategic Directions.
The report analyzes the following companies:
Mylan
Novartis
Pfizer
Sun Pharma
Teva
Individual company reports $950.
The report provides significant competitor information, analysis and insight critical to the development and implementation of effective marketing and R&D programs.
In the dynamic and fragmented Generic Drug industry, besieged by intense competition and rapid change of technological innovations, the ability to anticipate new product introductions and marketing strategies is particularly important...and can spell the difference between success and failure.
The reports objectives include:
- To assist potential market entrants in evaluating prospective acquisitions and joint venture candidates.
- To complement organizations internal competitor information gathering efforts with strategic analysis, data interpretation and insight.
2018 Biotechnology Research Review
Several significant developments have aided and accelerated development and growth of markets in biotechnology, in the period of review. Notable recent advancements in biotechnology are CRISPR, Spheroids for drug development,
View ReportBiomarker Deals: Terms, Value and Trends, 2008-2018
Report ScopeThis report represents a current and important business tool to evaluate terms and conditions of licensing, acquisitions and partnerships deals in the biomarker sector. The geographic scope of this
View ReportGlobal Generic Drugs Market, By Type (Small Molecule Generics vs Biosimilars), By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, Others), By Drug Delivery (Oral, Topical, Parenteral, Others), By Form (Tablet, Capsule, Injection, Others), By Source (In House vs Contract Manufacturing Organizations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Company, By Region, Forecast & Opportunities, 2026
Global generic drugs market was valued at USD371.04 billion in 2020 and is anticipated to reach USD564.43 billion until 2026 by witnessing a CAGR of 7.08% during the forecast period.
View Report2021 Generic Drugs: Leading Companies Capabilities, Goals and Strategies
This report is part of the Competitive Analysis Series prepared by to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation to
View ReportFill The Form For Sample Request